The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Incidence and survival among young women with stage I-III breast cancer: Seer 2000-2015
Abstract
Background: Although recent findings suggest that de novo stage IV breast cancer is increasing in premenopausal women in the United States, contemporary incidence and survival data are lacking for stage I–III cancer. Methods: Women aged 20–29 (n = 3826), 30–39 (n = 34 585), and 40–49 (n = 126 552) years who were diagnosed with stage I–III breast cancer from 2000 to 2015 were identified from the Surveillance, Epidemiology, and End Results 18 registries database. Age-adjusted, average annual percentage changes in incidence and 5- and 10-year Kaplan-Meier survival curves were estimated by race and ethnicity, stage, and hormone receptor (HR) status and grade (low to well and moderately differentiated; high to poorly and undifferentiated) for each age decade. Results: The average annual percentage change in incidence was positive for each age decade and was highest among women aged 20–29 years. Increased incidence was driven largely by HR+ cancer, particularly HR+ low-grade cancer in women aged 20–29 and 40–49 years. By 2015, incidence of HR+ low- and high-grade cancer each independently exceeded incidence of HR− cancer in each age decade. Survival for HR+ low- and high-grade cancer decreased with decreasing age; survival for HR− cancer was similar across age decades. Among all women aged 20–29 years, 10-year survival for HR+ high-grade cancer was lower than that for HR+ low-grade or HR− cancer. Among women aged 20–29 years with stage I cancer, 10-year survival was lowest for HR+ high-grade cancer. Conclusions: HR+ breast cancer is increasing in incidence among premenopausal women, and HR+ high-grade cancer was associated with reduced survival among women aged 20–29 years. Our findings can help guide further evaluation of preventive, diagnostic, and therapeutic strategies for breast cancer among premenopausal women.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Non-Hispanic Black women also had the highest incidence for advanced staged disease, which likely contributes to their higher mortality rates.17,18,19”
From Breast Cancer Incidence Among US Women Aged 20 to 49 Years by Race, Stage, and Hormone Receptor Status (2024) · cites this paper as [18]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hershman, D. L., Shao, T., Kushi, L. H., Buono, D., Tsai, W. Y., Fehrenbacher, L., Kwan, M., Gomez, S. L., & Neugut, A. I. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-1132-4 · Cited by 870
Zhang, N. R., & Siegmund, D. O. (2007) · Biometrics · doi:10.1111/j.1541-0420.2006.00662.x · Cited by 407 · cited 1×
“Piecewise regression models also were assessed via a modified Bayesian information criterion model selection method (27) and fit using the Joinpoint software.”
MethodHuiart, L., Bouhnik, A.-D., Rey, D., Tarpin, C., Cluze, C., Bendiane, M. K., Viens, P., & Giorgi, R. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.03.004 · Cited by 97 · cited 1×
“Young age also has been associated with lower adherence to antiestrogen therapies (43), which itself has been associated with increased mortality (44).”
Background
Research works printed but not linked: 47
- Partridge, 2016, Subtype-dependent relationship between young age at diagnosis and breast cancer survival, J Clin Oncol, 34, 3308, 10.1200/JCO.2015.65.8013 · DOI · Paper page
- Azim, 2014, Biology of breast cancer in young women, Breast Cancer Res, 16, 427., 10.1186/s13058-014-0427-5 · DOI · Paper page
- Anders, 2011, Breast carcinomas arising at a young age: unique biology or a surrogate for aggressive intrinsic subtypes?, J Clin Oncol, 29, e18, 10.1200/JCO.2010.28.9199 · DOI · Paper page
- Azim, 2012, Elucidating prognosis and biology of breast cancer arising in young women using gene expression profiling, Clin Cancer Res, 18, 1341, 10.1158/1078-0432.CCR-11-2599 · DOI · Paper page
- Lambertini, 2016, The prognostic performance of Adjuvant! Online and Nottingham Prognostic Index in young breast cancer patients, Br J Cancer, 115, 1471, 10.1038/bjc.2016.359 · DOI
- Gnerlich, 2009, Elevated breast cancer mortality in women younger than age 40 years compared with older women is attributed to poorer survival in early-stage disease, J Am Coll Surg, 208, 341, 10.1016/j.jamcollsurg.2008.12.001 · DOI · Paper page
- Collins, 2012, Pathologic features and molecular phenotype by patient age in a large cohort of young women with breast cancer, Breast Cancer Res Treat, 131, 1061, 10.1007/s10549-011-1872-9 · DOI · Paper page
- Ruddy, 2014, Breast cancer presentation and diagnostic delays in young women, Cancer, 120, 20, 10.1002/cncr.28287 · DOI · Paper page
- Johnson, 2016, Access to care in Vermont: factors linked with time to chemotherapy for women with breast cancer—a retrospective cohort study, J Oncol Pract, 12, e848, 10.1200/JOP.2016.013409 · DOI
- Primeau, 2014, Social service barriers delay care among women with abnormal cancer screening, J Gen Intern Med, 29, 169, 10.1007/s11606-013-2615-x · DOI
- Rosenberg, 2016, BRCA1 and BRCA2 mutation testing in young women with breast cancer, JAMA Oncol, 2, 730, 10.1001/jamaoncol.2015.5941 · DOI
- Malone, 2006, Prevalence and predictors of BRCA1 and BRCA2 mutations in a population-based study of breast cancer in white and black American women aged 35 to 64 years, Cancer Res, 66, 8297, 10.1158/0008-5472.CAN-06-0503 · DOI · Paper page
- Valencia, 2017, The role of genetic testing in patients with breast cancer: a review, JAMA Surg, 152, 589, 10.1001/jamasurg.2017.0552 · doi:10.1001/jamasurg.2017.0552
- 2000, Anglian Breast Cancer Study Group. Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases., Br J Cancer, 83, 1301, 10.1054/bjoc.2000.1407 · DOI · Paper page
- Nguyen, 2018, Breast cancer diagnosed during pregnancy is associated with enrichment of non-silent mutations, mismatch repair deficiency signature and mucin mutations, NPJ Breast Cancer, 4
- Hartman, 2016, The prognosis of women diagnosed with breast cancer before, during and after pregnancy: a meta-analysis, Breast Cancer Res Treat, 160, 347, 10.1007/s10549-016-3989-3 · DOI · Paper page
- Bouchardy, 2007, Recent increase of breast cancer incidence among women under the age of forty, Br J Cancer, 96, 1743, 10.1038/sj.bjc.6603783 · doi:10.1038/sj.bjc.6603783
- Pollan, 2009, Recent changes in breast cancer incidence in Spain 1980-2004, J Natl Cancer Inst, 101, 1584, 10.1093/jnci/djp358 · DOI
- Merlo, 2012, Breast cancer incidence trends in European women aged 20-39 years at diagnosis, Breast Cancer Res Treat, 134, 363, 10.1007/s10549-012-2031-7 · doi:10.1007/s10549-012-2031-7
- Johnson, 2013, Incidence of breast cancer with distant involvement among women in the United States, 1976 to 2009, JAMA, 309, 800, 10.1001/jama.2013.776 · DOI · Paper page
- Greene, 2002, The American Joint Committee on Cancer: updating the strategies in cancer staging, Bull Am Coll Surg, 87, 13
- Roberti, 1997, The role of histologic grading in the prognosis of patients with carcinoma of the breast: is this a neglected opportunity?, Cancer, 80, 1708, 10.1002/(SICI)1097-0142(19971101)80:9<1708::AID-CNCR3>3.0.CO;2-A · doi:10.1002/(sici)1097-0142(19971101)80:9<1708::aid-cncr3>3.0.co;2-a
- Hammond, 2010, American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer, J Clin Oncol, 28, 2784, 10.1200/JCO.2009.25.6529 · DOI · Paper page
- Sun, 2017, Germline mutations in cancer susceptibility genes in a large series of unselected breast cancer patients, Clin Cancer Res, 23, 6113, 10.1158/1078-0432.CCR-16-3227 · DOI · Paper page
- Keramatinia, 2014, Trends in incidence of breast cancer among women under 40 in Asia, Asian Pac J Cancer Prev, 15, 1387, 10.7314/APJCP.2014.15.3.1387 · doi:10.7314/apjcp.2014.15.3.1387
- Leclere, 2013, Trends in incidence of breast cancer among women under 40 in seven European countries: a GRELL cooperative study, Cancer Epidemiol, 37, 544, 10.1016/j.canep.2013.05.001 · DOI
- Guo, 2018, Trends in breast cancer mortality by stage at diagnosis among young women in the United States, Cancer, 124, 3500, 10.1002/cncr.31638 · DOI · Paper page
- Copson, 2013, Prospective observational study of breast cancer treatment outcomes for UK women aged 18-40 years at diagnosis: the POSH study, J Natl Cancer Inst, 105, 978, 10.1093/jnci/djt134 · DOI · Paper page
- Lian, 2017, The impact of young age for prognosis by subtype in women with early breast cancer, Sci Rep, 7, 11625., 10.1038/s41598-017-10414-x · DOI
- DeSantis, 2017, Breast cancer statistics, 2017, racial disparity in mortality by state, CA Cancer J Clin, 67, 439, 10.3322/caac.21412 · DOI · Paper page
- Francis, 2018, Tailoring adjuvant endocrine therapy for premenopausal breast cancer, N Engl J Med, 379, 122, 10.1056/NEJMoa1803164 · DOI · Paper page
- Francis, 2015, Adjuvant ovarian suppression in premenopausal breast cancer, N Engl J Med, 372, 436, 10.1056/NEJMoa1412379 · DOI · Paper page
- Pagani, 2014, Adjuvant exemestane with ovarian suppression in premenopausal breast cancer, N Engl J Med, 371, 107, 10.1056/NEJMoa1404037 · DOI · Paper page
- Burstein, 2016, Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of Clinical Oncology Clinical Practice Guideline update on ovarian suppression, J Clin Oncol, 34, 1689, 10.1200/JCO.2015.65.9573 · DOI · Paper page
- Lambertini, 2019, Adjuvant anti-HER2 therapy, treatment-related amenorrhea, and survival in premenopausal HER2-positive early breast cancer patients, J Natl Cancer Inst, 111, 86, 10.1093/jnci/djy094 · DOI
- Ganz, 2011, Menstrual history and quality-of-life outcomes in women with node-positive breast cancer treated with adjuvant therapy on the NSABP B-30 trial, J Clin Oncol, 29, 1110, 10.1200/JCO.2010.29.7689 · DOI
- Vanhuyse, 2005, Chemotherapy-induced amenorrhea: influence on disease-free survival and overall survival in receptor-positive premenopausal early breast cancer patients, Ann Oncol, 16, 1283, 10.1093/annonc/mdi241 · doi:10.1093/annonc/mdi241
- Llarena, 2015, Impact of fertility concerns on tamoxifen initiation and persistence, J Natl Cancer Inst, 107, 10.1093/jnci/djv202 · DOI
- Pagani, 2015, Pregnancy after breast cancer: are young patients willing to participate in clinical studies?, Breast, 24, 201, 10.1016/j.breast.2015.01.005 · DOI
- Freedman, 2012, Receipt of locoregional therapy among young women with breast cancer, Breast Cancer Res Treat, 135, 893, 10.1007/s10549-012-2156-8 · DOI
- Zimmer, 2018, Analysis of breast cancer in young women in the Department of Defense (DOD) database, Breast Cancer Res Treat, 168, 501, 10.1007/s10549-017-4615-8 · DOI
- Copson, 2018, Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study, Lancet Oncol, 19, 169, 10.1016/S1470-2045(17)30891-4 · DOI · Paper page
- Fidler, 2017, Cancer incidence and mortality among young adults aged 20-39 years worldwide in 2012: a population-based study, Lancet Oncol, 18, 1579, 10.1016/S1470-2045(17)30677-0 · DOI · Paper page
- Kerlikowske, 2011, Comparative effectiveness of digital versus film-screen mammography in community practice in the United States: a cohort study, Ann Intern Med, 155, 493, 10.7326/0003-4819-155-8-201110180-00005 · DOI · Paper page
- Madhavan, 2014, Plasma DNA integrity as a biomarker for primary and metastatic breast cancer and potential marker for early diagnosis, Breast Cancer Res Treat, 146, 163, 10.1007/s10549-014-2946-2 · DOI · Paper page
- Uehiro, 2016, Circulating cell-free DNA-based epigenetic assay can detect early breast cancer, Breast Cancer Res, 18, 129., 10.1186/s13058-016-0788-z · DOI
- Tang, 2016, Blood-based DNA methylation as biomarker for breast cancer: a systematic review, Clin Epigenetics, 8, 10.1186/s13148-016-0282-6 · DOI · Paper page
Cited by
Gupta, G. K., Collier, A. L., Lee, D., Hoefer, R. A., Zheleva, V., Siewertsz van Reesema, L. L., Tang-Tan, A. M., Guye, M. L., Chang, D. Z., Winston, J. S., et al. (2020) · Cancers · doi:10.3390/cancers12092392 · Cited by 331
Xu, S., Murtagh, S., Han, Y., Wan, F., & Toriola, A. T. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.53331 · Cited by 178
Metadata
- Authors
- Thomas, A., Rhoads, A., Pinkerton, E., Schroeder, M. C., Conway, K. M., Hundley, W. G., McNally, L. R., Oleson, J., Lynch, C. F., & Romitti, P. A.
- Affiliations
- Department of Internal Medicine, Wake Forest University School of Medicine, Wake Forest University, Winston-Salem, NC
- Department of Epidemiology, College of Public Health, Division of Health Services Research, Department of Biostatistics, , University of Iowa, Iowa City, IA
- College of Pharmacy, University of Iowa, Iowa City, IA
- Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA
- Department of Cancer Biology, Wake Forest University School of Medicine, Wake Forest University, Winston-Salem, NC
- College of Public Health, University of Iowa, Iowa City, IA
- Venue
- JNCI Cancer Spectrum
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-06-07
- Volume
- 3
- Issue
- 3
- ISSN
- 2515-5091
- Cited by
- 68
- References
- 3
- Language
- en
- Funders
- Centers for Disease Control and Prevention (U01DD001035, U01DD001223)
- National Cancer Institute (HHSN2612013000201)
- Nealie Belk Stevens Fund for Breast Cancer Research
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.